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AbstRACt
background: Postpartum hemorrhage (PPH) is a major cause of maternal mortality globally. Tranexamic acid, an 
anti‑fibrinolytic agent, is a novel approach to prevent this dreadful complication. This study aims to document the efficacy of 
intravenous (IV) tranexamic acid in reducing blood loss during and after cesarean section (CS). 
Materials and Methods: In this prospective, randomized, placebo‑controlled, open‑label study, 100 mothers scheduled for 
elective CS were randomly selected and divided into two groups (study and control) of 50 each. The study group received 1 g 
IV tranexamic acid and the control group received IV placebo. Following delivery, all mothers received 10 units of oxytocin 
in 500 mL of normal saline. 
Results: The mean intraoperative and postpartum blood loss were significantly lower in the study group than the control 
group: 499.11 ± 111.2 ml and 59.93 ± 12.5 ml versus 690.85 ± 198.41 ml and 110.06 ± 13.47ml, respectively (P < 0.001). 
Total blood loss was 30% less in the study group (P < 0.001). Six mothers had PPH in the control group while none in the 
study group had PPH. The difference between the preoperative and postoperative hemoglobin values was significantly 
less in the study group than the control group, 0.26 ± 0.22 g% versus 0.99 ± 0.48 g% (P < 0.001).There was no significant 
difference with respect to other hematologic parameters. There was no added adverse effect or need for NICU admission 
in the study group. 
Conclusion: Preoperative IV tranexamic acid significantly reduced blood loss during elective CS without any significant 
adverse effects.
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Background
Postpartum hemorrhage (PPH) is a major complication 
after both vaginal and cesarean delivery worldwide, which 
contributes substantially to maternal mortality and near 
misses. Each year, approximately 1–2% of mothers with PPH 
die, with an average interval of approximately 2–4 hours from 
onset of PPH to death.[1] PPH is defined as the loss of more 
than 500 mL of blood following normal delivery or more than 
1000 mL loss following cesarean section (CS).[2] There are four 
causes of PPH – uterine atony, trauma to the birth passage, 
retained placental tissue or membranes, and coagulopathies 
such as disseminated intravascular coagulation (DIC).[3] PPH 
can reach disastrous proportions during CS.
Management of hemorrhage after CS may range from 
administration of oxytocic and blood transfusion to 
more radical measures such as hysterectomy.[4,5] Use of 
anti-fibrinolytic agents such as tranexamic acid (TXA), 
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however, avoids both the hazards of blood transfusion as 
well as the long-term side-effects of hysterectomy.
The aim of this study is to assess the effect of intravenous (IV) 
TXA on blood loss during and after CS.
Materials and Methods
A randomized, placebo-controlled, open-label clinical study 
was conducted after Institutional Ethics Committee approval 
from May 2012 to April 2013 with 100 clinically stable 
singleton antenatal mothers (aged 20–40 years) at term 
scheduled for elective CS. Pregnancy complications such 
as pre-eclampsia, polyhydramnios, macrosomia, multiple 
pregnancy, preterm labor, placenta previa, and abruptio 
placentae were excluded from the study along with mothers 
suffering from blood dyscrasias, coagulation disorders, 
thromboembolic disorders, severe anemia, allergy to TXA, 
and severe medical and surgical complications involving the 
heart, liver, or kidney.
Sample size was calculated assuming that a difference of 
100 mL of total (intra and postoperative) blood loss would 
be a clinically important difference between the two groups. 
It was calculated that 45 participants would be required 
per group to detect this difference with 80% power and 5% 
probability of Type 1 error. Standard deviation was assumed 
to be 190 for control group and 150 for the test group 
based on an earlier study.[6] Adjusting for 10% dropout rate, 
recruitment target was set at 50 participants per group. 
Figure 1 shows a summary of study design.
The selected 100 mothers were randomized into two 
groups using a computer-generated randomization list to 
receive either 1 g (in 10 mL) of IV TXA dissolved in 20 mL 
of 5% dextrose solution (study group; n = 50) or IV placebo, 
i.e. 30 mL of 5% dextrose solution (control group; n = 50), 
20 minutes before beginning spinal anesthesia. During CS, 
after draining the amniotic fluid completely and delivery of 
placenta, blood was drained in a separate suction container. 
Dry and soaked mops and sheets were weighed by a sensitive 
weighing machine.
Mean blood loss from mops and sheets was calculated 
using the formula used by Gai et al.:[7] blood from mops 
and sheets = (weight of soaked material – weight of dry 
material)/1.05; where 1.05 is the specific gravity of blood at 
37°C. To this, the blood drained in the suction container after 
delivery of placenta was added to get the total intraoperative 
blood loss.
After delivery, 10 units of oxytocin in 500 mL of normal 
saline was infused intravenously every 20 to 30 minutes. 
Additional 15 units of oxytocin was given postoperatively (5 U 
in each bottle of IV fluid for three consecutive bottles over a 
period of 12 hours). Further administration of oxytocin was 
according to requirement. Two-hour postoperative blood loss 
was calculated from the soaked pads by the same formula 
mentioned above.
Two hours postoperative vitals (pulse, systolic and diastolic 
blood pressure, respiratory rate, and pallor) were compared 
with the preoperative status in both groups. Pre- and 24-hour 
postoperative complete blood count, coagulation profile, 
liver function test, and renal function test were compared 
between the two groups.
Results
The data was expressed as mean ± SD, frequency, and percentage. 
A preliminary test of normalcy (Kolmogorov–Smirnov test) 
was carried out for the distribution of the data. Numerical 
variables were compared with independent sample t-test and 
Mann–Whitney U test, while categorical variables were dealt 
with Chi-square test and Fisher’s exact test as appropriate. 
Two-tailed P value of <0.05 was considered significant. For 
data analysis, standard statistical software such as Microsoft 
Excel and SPSS version 11.5 were utilized.
Table 1 shows that the two groups were equally matched 
with respect to demographic characteristics (viz. age, weight, 
height, gravida, parity), period of gestation at which CS was 
done, indications for elective CS, preoperative vitals (pulse, 
systolic blood pressure, diastolic blood pressure, respiratory 
rate, pallor), and preoperative hematological work-up such 
as complete blood count, liver function tests, and renal 
function tests.
Table 2 shows that both intraoperative and 2-hour 
postoperative blood loss were significantly less in the study 
group than the control group.
113 patients were intitially screened
103 patients considered for study
100 patients were finally selected for the study
Randomization
3 patients refused to give
 consent for the study
Reasons for exclusion (n = 10): 
Vaginal delivery 6, Emergency
 LSCS 4 (fetal distress 2,
 scar tenderness 2)
Study group; n = 50 Control group; n = 50
Figure 1: Summary of study design
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Table 3 shows the postoperative status of the study and 
control groups. Comparison of 2-hour postoperative vitals 
between the two groups showed that pallor (P = 0.004) and 
pulse rate (P = 0.000) were significantly lower in the study 
group. Systolic blood pressure, diastolic blood pressure, and 
respiratory rate did not have any significant difference in the 
two groups postoperatively. Postoperative fall in hemoglobin 
percent was significantly more in control (0.99 g%) group than 
study group (0.26 g%) (P = 0.000). Other parameters, viz. total 
count, platelet count, prothrombin time and activated plasma 
thromboplastin time, bilirubin and liver enzymes, urea, and 
creatinine did not have any significant difference in the two 
groups. There was no significant difference in APGAR values at 
1 min (P = 0.559) and 5 min (P = 0.910) between the groups. 
The incidences of adverse effects such as nausea, vomiting, 
and diarrhoea were not significantly increased in the study 
group compared to the control group. There was no evidence 
of thrombosis in any of the mothers in the study group.
Discussion
TXA exerts its antifibrinolytic effect by blocking the lysine 
binding locus of the plasminogen and plasmin molecules, 
thereby preventing the binding of plasminogen and plasmin 
to the fibrin substrate. TXA also inhibits conversion of 
plasminogen to plasmin.[8] After delivery of the baby, there is 
transient activation of fibrinolytic cascade for 6 to 10 hours.[7] 
Hence, the efficacy of an antifibrinolytic agent such as TXA 
is being evaluated for the prevention of PPH.
The results show that, intraoperatively, mothers in the 
study group had a mean blood loss of 499.11 ± 111.2 mL, 
while mothers in control group had a mean blood loss of 
690.85 ± 198.41 mL (P = 0.000). Two hours postoperatively, 
the study group had a mean blood loss of 59.93 ± 12.5 mL, 
while the control group had a mean blood loss of 
110.06 ± 13.47 mL (P = 0.000). Coupling the two results, 
mothers in the study group had a mean total blood loss of 
559.68 ± 113.80 mL, while mothers in the control group 
had a mean total blood loss of 800.91 ± 200.26 mL. Thus, 
in the study group, there was total reduction in blood loss 
by approximately 30% (P = 0.000). Six mothers in the control 
group required extra 10 U of oxytocin infusion, while only 
two of the mothers in the TXA group required the same.
Movafegh et al.[6] performed their study with intravenous 
administration of 10 mg/kg of TXA 20 minutes before 
skin incision at cesarean delivery. Mean blood loss was 
significantly less in the TXA group compared with the control 
group for both intraoperative bleeding (262.5 ± 39.6 versus 
404.7 ± 94.4 mL) and postoperative bleeding (67.1 ± 6.5 
Table 1: Demographic characteristics and pre-operative vitals 
and blood work-up





Age (years) 25.00±4.71 25.88±5.39 0.387*
Weight (kg) 65.22±5.58 64.86±8.476 0.803*
Height (m) 1.55±0.04 1.55±0.04 0.889*
Gravida 1st 28 (56%) 31 (62%) 0.45#
2nd 20 (40%) 19 (38%)
3rd 2 (4%) 0
Parity Null 33 (66%) 36 (72%) 0.48#
1st 16 (32%) 14 (28%)
2nd 1 (2%) 0
Period of gestation (weeks) 38.92±1.38 39.02±1.42 0.722*
Indications for LSCS
Postdated pregnancy 14 (28%) 11 (22%) 0.945^
CPD 13 (26%) 14 (28%)
Previous 1 or 2 LSCS 9 (18%) 11 (22%)
Malpresentations 9 (18%) 8 (16%)
Elderly primi 5 (10%) 6 (12%)
Pallor present 22 29 0.161^
Absent 28 21
Pulse (per minute) 81.64±8.17 84.04±6.92 0.116*
SBP (mmHg) 117.56±8.25 116.00±8.52 0.355*
DBP (mmHg) 74.12±6.08 73.76±8.72 0.787#
Respiratory rate (per 
minute)
13.64±1.39 12.92±2.10 0.057#
Hb (g%) 10.33±1.26 9.80±1.34 0.050*
Total count (per cc) 9250.48±1391.16 9149.46±1271.68 0.706*
Platelet count (lacs/cc) 2.1±0.62 2.16±0.62 0.589*
PT (s) 11.86±0.17 11.87±0.17 0.651*
aPTT (s) 31.53±0.93 31.51±0.86 0.894*
Bilirubin (T) 1.00±0.27 1.04±0.25 0.493*
Bilirubin (D) 0.26±0.14 0.28±0.15 0.551#
ALT (IU/ml) 38.34±4.17 38.92±3.99 0.480*
AST (IU/ml) 39.94±4.99 38.18±4.86 0.212*
Urea 22.66±1.80 22.52±1.78 0.655#
Creatinine 0.80±0.20 0.79±0.19 0.805*
P calculated using. *Independent sample t‑test, #Mann‑Whitney U test and ^Chi‑square 
test
Table 2: Pre and postoperative blood loss estimation
Parameters Study group (n=50) (mean±SD) Control group (n=50) (mean±SD) Significance
Blood volume in suction (ml) 98.64±28.89 220.80±64.48 P<0.001*
Blood volume in mops + sheets (ml) 401.11±112.43 470.05±141.07 P<0.01*
Blood loss ‑ intraoperative (ml) 499.75±111.20 690.85±198.41 P<0.001*
Blood loss ‑ 2 h postoperative (ml) 59.93±12.5 110.06±13.47 P<0.001*
Total blood loss 559.68±113.80 800.91±200.26 P<0.001*
P calculated using. *Independent sample t‑test
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versus 141.0 ± 33.9 mL; P < 0.001). Oxytocin administration 
was significantly less in the TXA group compared with the 
control group (39 ± 5.8 vs. 43 ± 5.4 units; P = 0.001). These 
results were consistent with the present study.
A similar study was carried out by Gai et al.[7] in China 
by administering TXA 10 min before skin incision. This 
intervention led to less bleeding 2 hours postoperatively: 
42.75 ± 40.45 mL in the study group versus 73.98 ± 77.09 mL 
in the control group (P = 0.001), but did not show any 
decrease in post-placental delivery blood loss. This was 
probably due to the fact that TXA was administered only 
10 min before the skin incision. Thus, the present study was 
designed to administer TXA 20 min before spinal anesthesia.
Sekhavat et al.[9] conducted a prospective randomized study 
on 90 primipara mothers which showed that TXA significantly 
reduced blood loss from the end of CS to 2 hours postpartum; 
28.02 ± 5.53 mL blood loss in the tranexamic group versus 
37.12 ± 8.97 mL in the control group (P = 0.000). These 
results were comparable to our study although they studied 
only primipara, whereas our study had no inclusion criteria 
based on parity.
In our study, postoperatively, there was significantly more 
pallor in the control group than the study group (38 versus 
24) (P = 0.004). There was also significant increase in 
pulse, mean 84/min in study group versus 92/min in control 
group (P = 0.000). Other parameters such as systolic blood 
pressure, diastolic blood pressure, and respiratory rate did 
not have any significant difference in the two groups. In 
the study by Movafegh et al.[6] and Gai et al.,[7] there was no 
significant increase in pulse as well as other postoperative 
vitals.
There was significant difference in postoperative hemoglobin 
levels between the two groups, mean concentration 
being 10.0 g% in the study group versus 8.8 g% in the 
control group (P = 0.000). The difference between the 
preoperative and postoperative hemoglobin values was 
also significantly less in the study group than the control 
group (P value = 0.000). Other hematologic and biochemical 
parameters did not have any significant difference in the two 
groups. These results were comparable with the study by 
Movafegh et al.[6] and Gai et al.[7]
Side-effect profile of TXA such as nausea, vomiting, and 
diarrhoea was similar in both groups. These results were 
Table 3: Postoperative vitals, blood work-up, APGAR score of neonate, and side-effects of drug
Parameters Study group (n=50) (mean±SD or %) Control group (n=50) (mean±SD or %) P
Pallor ‑ present 24 (48%) 38 (76%) 0.004^
Absent 26 (52%) 12 (24%)
Pulse (per min) 83.76±7.52 91.6±5.07 0.000*
SBP (mmHg) 111.80±8.827 108.6±10.184 0.096*
DBP (mmHg) 68.44±6.011 69.32±7.22 0.753#
Respiratory rate(/min) 14.38±1.22 14.00±1.71 0.493*
Hb% (g%) 10.08±1.18 8.81±1.18 0.000#
Hb% difference 0.26±0.22 0.99±0.48 0.000*
(pre‑op and post‑op)
Total count (per cc) 9354.80±1383.91 9243.20±1267.12 0.675*
Platelet count (lacs/cc) 1.94±0.62 2.03±0.62 0.493*
PT (s) 11.78±0.16 11.79±0.16 0.712*
aPTT (s) 31.78±0.91 31.7±0.83 0.750*
Bilirubin (T) 0.83±0.18 0.86±0.19 0.535*
Bilirubin (D) 0.19±0.09 0.21±0.10 0.573#
ALT 41.18±4.95 41.60±4.84 0.669*
AST 37.8±4.42 38.78±4.39 0.226#
Urea 22.08±1.54 21.96±1.48 0.739#
Creatinine 0.75±0.17 0.75±0.16 0.910#
APGAR score 1 minute 7.06±1.25 7.18±1.35 0.559#
5 minutes 8.66±1.00 8.64±0.98 0.910#
Side effects
Nausea 16 (32%) 13 (26%) 0.059^
Vomiting 9 (18%) 8 (16%) 0.790^
Diarrhoea 1 (2%) 0 (0%) 0.315^
Thrombosis 0 (0%) 0 (0%)
P calculated using. *Independent sample t‑test, #Mann‑Whitney U‑test and ^Chi‑square test
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similar to previous studies. The incidence of thrombosis 
during pregnancy and puerperium is 5–6 times higher than 
that in the general population. When the anti-fibrinolytic 
drug TXA is administered, the increased risk of thrombosis 
should be considered, especially in the postpartum LSCS 
population. In our study, however, none of the mothers 
developed signs of thrombosis. Svanberg et al.[10] reported 
67 cases of abruptio placentae being treated by TXA without 
any signs of thrombosis in any. Similar results were found 
in other studies.[6,7,9] All data demonstrated that TXA can be 
used safely without increasing the occurrence of thrombosis, 
but still more studies are needed in this regard.
The safety of giving TXA (1 g) while the fetus was still 
in utero was a key concern. As a consequence, the neonatal 
outcome was meticulously evaluated by a neonatologist. In 
the current study, the mean APGAR scores at 1 and 5 min 
were 7.06 ± 1.25 and 8.66 ± 1.00 in the study group and 
7.18 ± 1.35 and 8.64 ± 0.98 in the control group, respectively. 
Thus, there was no significant difference in the APGAR values 
at 1 min (P = 0.559) and at 5 min (P = 0.910) among the two 
groups. None of the babies required NICU admission. Results 
were comparable to previous studies.[6,7,9,11,12]
To conclude, antenatal administration of intravenous TXA 
20 min before spinal anesthesia significantly reduces the 
amount of blood loss during and after lower segment 
caesarean section without any untoward adverse effects on 
the mother or the baby.
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